Cepheid
This article was originally published in The Gray Sheet
Executive Summary
Maker of microfluidic systems for detection and analysis of nucleic acids raises $34.5 mil. in its initial public offering, the company announces July 13 (1"The Gray Sheet" July 3, p. 11). With exercise of 750,000 over-allotment shares by underwriters UBS Warburg, Prudential Vector Healthcare and Invemed Associates, the IPO included a total of 5.75 mil. shares at $6 each. Proceeds will be used for R&D and expansion of manufacturing. Cepheid shares trade on the Nasdaq exchange under the symbol "CPHD"
You may also be interested in...
Cepheid
Initial public offering of 5 mil. shares at $6 each June 21 represents a reduction in the originally proposed price range of $10-12 per share (1"The Gray Sheet" May 1, p. 19). The Sunnyvale, California maker of microfluidic systems for detection and analysis of nucleic acids plans to use the proceeds from the $30 mil. offering for R&D, expansion of manufacturing and other general corporate purposes. Cepheid shares trade on the Nasdaq market under the symbol "CPHD." Underwriters UBS Warburg, Prudential Vector Healthcare and Invemed Associates hold an overallotment option for 750,000 additional shares
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.